Engflag

Dementa

Quick links to important sections

Dementa

There is no image.

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dementa

Quick Facts

Property Description
Active Ingredient Memantine Hydrochloride
Forms Immediate-release tablets, oral solution, extended-release capsules
Pharmacological Class NMDA Receptor Antagonist (Anti-Alzheimer's agent)
General Purpose Support for cognitive function and memory
Origin Synthetic Adamantane derivative

What Type of Medicine is Dementa (Memantine Hydrochloride)?

Dementa is a prescription-only medication containing the active ingredient Memantine Hydrochloride (Memantine HCl), classified as an N-methyl-D-aspartate (NMDA) Receptor Antagonist. This classification is clinically recognized for its unique mechanism in managing certain neurodegenerative processes. Memantine, the active entity, is a synthetic compound derived from adamantane, distinguishing it as a molecule specifically engineered for central nervous system modulation.

The core function of an NMDA Receptor Antagonist is to modulate the glutamatergic system—the brain's primary pathway for rapid signaling critical for memory and thinking. Memantine's chemical structure and function relate to its role in neural communication.

What is the General Purpose and Form of Dementa?

The general purpose of Dementa is to provide fundamental support for stable cognitive function, including processes like memory and reasoning, typically within the geriatric population. The medication is intended for oral administration and is a monotherapy product, meaning it contains only one active ingredient. It is available in several dosage forms, which include immediate-release tablets, an oral solution (liquid), and extended-release capsules.

This range of forms is a key feature, allowing healthcare providers to tailor administration to individuals, particularly those who may have difficulty swallowing. This ensures consistent delivery of the active substance, Memantine Hydrochloride, which is required for effective, chronic management.

How Does Dementa Differ from Other Cognitive-Support Agents?

Dementa distinguishes itself by acting on the glutamate system, providing a unique non-overlapping mechanism compared to other pharmacological classes, such as cholinesterase inhibitors. While many established agents work by increasing acetylcholine levels, Memantine Hydrochloride operates via a distinct strategy: a selective antagonism of the NMDA receptor. This specialized action is designed to prevent excessive nerve cell stimulation (or excitotoxicity) caused by abnormal glutamate signaling, while allowing normal communication to proceed. This targeted glutamatergic system modulation offers a unique approach that provides a foundational element in comprehensive support strategies.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Dementa?

The safety profile of Dementa (Memantine Hydrochloride) is based on adverse reactions observed in clinical trials and those reported post-marketing, categorized by frequency and the body systems affected as documented in regulatory sources.

Frequency and System-Organ Class

Adverse reactions are classified into frequency categories. Common effects (occurring in 1% to 10% of patients) frequently involve the Nervous System and Gastrointestinal systems, including dizziness, headache, constipation, somnolence, and confusion. Other common effects include hypertension, fatigue, and vomiting.

Effects classified as Uncommon (occurring in 0.1% to 1% of patients) may include cardiac failure and venous thrombosis/thromboembolism, as well as hallucinations and abnormal gait.

Serious Adverse Reactions and Restrictions

Serious adverse reactions reported during post-marketing surveillance, which are generally rare, cover conditions such as Acute renal failure, Pancreatitis, Hepatitis, and Stevens Johnson syndrome. Additionally, seizures have been reported in the clinical trial setting.

Specific safety constraints are outlined in the official labeling. The medication is contraindicated in patients with a known hypersensitivity to Memantine Hydrochloride or any excipients. Caution is mandated for patients with severe renal impairment and severe hepatic impairment, as reduced drug clearance may lead to accumulation. Furthermore, co-administration with other NMDA Antagonists (e.g., amantadine) requires caution due to the potential for increased central nervous system-related adverse effects. Conditions that raise urine pH may also lead to a decrease in Memantine clearance.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose manifestations and management for Dementa (Memantine Hydrochloride) is derived strictly from official government regulatory documents.

Documented Overdose Manifestations

Official regulatory sources note that overdose may present with a range of central nervous system (CNS) and systemic effects. Documented manifestations include agitation, confusion, dizziness, somnolence, lethargy, and visual hallucinations. More severe signs reported in regulatory documents include coma, loss of consciousness, and diplopia (double vision). Potential cardiovascular effects are also documented, such as bradycardia (slowed heart rate), increased blood pressure (hypertension), and specific ECG changes.

Required Emergency Actions

In cases of suspected overdose, urgent medical help must be sought immediately. Regulators advise that patients contact a poison control center for the latest management recommendations.

  • Supportive Management: The official label documents that there is no specific antidote available for Memantine overdose. Management requires the use of general supportive measures and symptomatic treatment, addressing the specific clinical signs that are observed.
  • Physiological Considerations: Conditions that cause the urine to become alkaline (e.g., pH 8 or higher) can significantly reduce the renal clearance of the drug, leading to its accumulation in the body and a possible increase in adverse effects, a factor relevant in overdose risk assessment.

This information describes the required actions and expected clinical profile as outlined by regulatory authorities.

Therapeutic Uses of Dementa

Memantine (Dementa) is primarily utilized as supportive therapy for conditions characterized by progressive cognitive and functional decline, applied across domains where additional symptomatic support is needed. The medicine helps manage groups of symptoms that interfere with daily functioning and is considered relevant for easing the overall symptom load.

The primary indications for which it is commonly used to help with include Alzheimer's disease and associated dementia of the Alzheimer's type. The medication may improve the ability to think and remember or may assist with managing symptoms that interfere with daily functioning.

Therapeutic Support for Core Symptoms

This supportive role is used for managing symptoms related to intellectual deficits, such as persistent memory loss and confusion, as well as functional and behavioral challenges. Dementa plays a role in managing symptoms that interfere with daily functioning, is applied across domains where additional symptomatic support is needed, addressing symptoms that create noticeable functional strain related to routine daily activities and is relevant for easing symptoms related to heightened physiological activity, such as agitation.

“The medication contributes to maintaining a sense of stability when symptoms are more noticeable, which supports patients during episodes of heightened discomfort.”

Quick Fact Relief for Symptom
Primary Focus Cognitive Decline (memory and thinking)
Secondary Focus Behavioral Symptoms (agitation and restlessness)
Context Chronic neurodegenerative disease management

Regulatory References

  1. NIH MedlinePlus overview of Memantine

Eligibility and Restrictions for Use

Who Can and Cannot Use This Medicine

This section summarizes the official eligibility criteria for this medicine, based strictly on governmental regulatory documents from agencies like the FDA and EMA.

Absolute Exclusions (Contraindications)

Classification Who Must Not Use the Medicine
Hypersensitivity Patients with a known allergy to memantine hydrochloride or to any other ingredients (excipients) in the formulation.

Restricted or Not Recommended Use

Use of this medicine is restricted or not recommended in several key populations due to either a lack of established safety/efficacy data or a risk of drug accumulation in the body.

  • Pediatric Patients: Use in children and adolescents under 18 years of age is not recommended as safety and efficacy have not been established in this age group.
  • Severe Renal Impairment: Patients with severe kidney impairment must be administered a reduced maximum daily dose to prevent drug accumulation.
  • Severe Hepatic Impairment: Use in patients with severe liver impairment is not recommended due to a lack of regulatory data for this population.
  • Pregnancy and Breastfeeding: The medicine should not be used during pregnancy unless clearly necessary, and women are advised not to breastfeed while taking it, as the potential risk to the fetus or infant is not fully known.

Summary

The primary exclusion for use is an allergy to the drug. Beyond this, the official profile primarily restricts use based on age (not established for pediatric patients) and the status of key elimination organs, particularly the kidneys and liver.

What should I know about interactions with other medicines?

Dementa Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dementa (Memantine Hydrochloride) primarily through its elimination via the kidneys and its impact on the central nervous system (CNS).

Interaction Type Interacting Substances/Conditions Restriction/Monitoring Requirement
Renal Clearance Modulation Drugs that alkalinize the urine (e.g., Acetazolamide, Sodium Bicarbonate); Clinical conditions that raise urine pH (e.g., renal tubular acidosis). Clearance is reduced by mathbf80% under alkaline urine conditions, which may lead to drug accumulation.
Cationic Transport Competition Active substances that use the same renal transport system (e.g., Cimetidine, Ranitidine, Quinidine, Nicotine). Potential risk of increased plasma levels of memantine due to competition for tubular secretion.
Pharmacodynamic Synergy Other NMDA Antagonists (e.g., Amantadine, Ketamine, Dextromethorphan). Co-administration should be avoided (EMA) or approached with caution (FDA) due to the risk of increased CNS-related effects.
Impact on Other Drugs Warfarin (Oral Anticoagulants). Close monitoring of the International Normalized Ratio (INR) or Prothrombin Time is officially advised due to isolated post-marketing reports of INR increases.

Memantine undergoes minimal metabolism by CYP450 enzymes; thus, no significant pharmacokinetic interactions based on metabolism are expected. The effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced, and the effects of barbiturates and neuroleptics may be reduced. Alcohol consumption may increase the risk of dizziness and confusion.

Mechanism of Action

Dementa exerts its effect by acting as a highly selective allosteric modulator at the R D receptor system, targeting a distinct regulatory site. This interaction modifies the receptor's sensitivity to its natural mediators, which is associated with pathways involved in the regulation of neural excitability. This specific receptor binding consequently alters the downstream signal transduction cascade, specifically influencing the IP3/ DAG pathway. This alters the phosphorylation state of key intracellular proteins, which is critical for influencing long-term cellular function. The combined molecular and cellular effects modify activity within autonomic and humoral regulatory feedback systems. By adjusting activity within these complex pathways, Dementa contributes to the modulation of regulatory systems and supports a more regulated state, which leads to a balanced and appropriate output from the affected biological pathways.

Dosage and Administration Information

The administration of Dementa (Memantine) is based on a structured, mandatory gradual dose escalation process known as titration. The medicine is for oral use only, available as immediate-release (IR) tablets, extended-release (XR) capsules, and an oral solution. The core usage principle is to progressively increase the daily dose in small increments, typically at minimum weekly intervals, until the target maintenance dose is achieved.

For the IR formulation, the usual maintenance dose is 20 mg per day, which is typically administered as 10 mg twice daily (a divided dose). The XR capsule is designed for once-daily administration, with a maximum dose of 28 mg per day. The medication can be taken with or without food. Administration constraints differ by form: the XR capsule must be swallowed whole or its contents sprinkled onto soft food, but it must not be crushed, chewed, or divided.

Dosing requires adjustment for specific patient populations. For individuals with severe renal impairment (CrCl 5–29 mL/min), the maximum dose must be reduced to 10 mg per day for the IR form. Use is not recommended in severe hepatic impairment due to a lack of data. If a single dose is missed, it should not be doubled up; instead, the next dose should be taken at the scheduled time. Continued therapy is subject to regular reassessment of benefit and tolerance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dementa

Evidence for Use in Symptomatic Management in Alzheimer's Disease

Dementa was studied for individuals with Alzheimer's disease, a condition marked by functional limitations and changes in thinking abilities that research examined. Researchers conducted Randomized Controlled Trials (RCTs), comparing Dementa against a placebo or another treatment to see how symptoms evolved in the observed populations across various stages of the condition. Studies examined several outcomes reflecting daily functioning or activity level, as well as specific cognitive measures (thinking, memory, and reasoning skills).

Findings describe patterns observed in the studies where scale scores for cognition and daily activities data show patterns related to differences in the group receiving Dementa compared to the control group. However, the evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly. The relationship between the short-term scale changes and long-term effects are not fully established.

Evidence for Use in Symptomatic Management in Parkinson's Disease Dementia (PDD)

Dementa was studied for a separate set of focused studies for people diagnosed with Parkinson's Disease Dementia. The research primarily consisted of short-term RCTs that included participants who were also taking medications for their Parkinson's disease. These studies explored PDD-specific outcomes related to systemic or functional imbalance, such as measures of attention and executive functions. Studies report that some short-term changes were observed in some studies regarding these specific cognitive and global rating scores.

What Is Still Uncertain About Dementa

Despite numerous studies, evidence quality varies across studies, and certainty remains low regarding the full clinical significance of the small differences measured in many trials. Comparative evidence is lacking in head-to-head trials against all potential alternative treatments. Crucially, research provides context but not individual predictions. The findings contribute to the broader evidence landscape, but follow-up durations were limited in the most rigorous studies, leaving questions about outcomes over five or ten years unanswered. Data for certain groups remain insufficient, particularly for very old adults or those with complex co-existing conditions.

How should Dementa be stored and disposed of?

Storage and Disposal of Memantine Hydrochloride (Dementa)

Memantine hydrochloride, including tablets and capsules, must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).

Required Conditions

Condition Requirement
Temperature Keep from freezing; temperature excursions up to 30 C are acceptable.
Protection Store away from excessive heat, direct light, and excessive moisture.
Container Keep the medicine in a tight, closed container.
Child Safety Must be stored out of the sight and reach of children.

Disposal and Stability

The oral solution, if used, has a labeled in-use shelf-life and must be used within 3 months after the bottle is opened. Unused or expired medication must not be disposed of in household trash or down the drain. Disposal must be conducted according to local regulations as specified by governmental health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

Equivalent of Dementa found in:

A-Z Index: